Logo
x

Search category

Subscribe Now

Ascletis

Ascletis’ ASC11 Receives the US FDA’s IND Approval for the Treatment COVID-19

Ascletis’ ASC11 Receives the US FDA’s IND Approval for the Treatment COVID-19

Ascletis Reports Patients Dosing in Multiple-Dose Escalation P-I Clinical Trial of ASC10 for COVID-19

Ascletis Reports Patients Dosing in Multiple-Dose Escalation P-I Clinical Trial of ASC10 for COVID-19

Ascletis Reports First Patient Dosing in the P-II Clinical Trial of ASC41 for Liver Biopsy-Proven Non-Alcoholic Steatohepatitis

Ascletis Reports First Patient Dosing in the P-II Clinical Trial of ASC41 for Liver Biopsy-Proven Non-Alcoholic Steatohepatitis

Ascletis Reports First Patient Dosing in the P-IIb Expansion Cohort of ASC22 (envafolimab) for Chronic Hepatitis B

Ascletis Reports First Patient Dosing in the P-IIb Expansion Cohort of ASC22 (envafolimab) for Chronic Hepatitis B

Ascletis Presents Results of ASC22 (envafolimab) in P-IIb Trial for the Treatment of Chronic Hepatitis B at EASL ILC 2022

Ascletis Presents Results of ASC22 (envafolimab) in P-IIb Trial for the Treatment of Chronic Hepatitis B at EASL ILC 2022

Ascletis Reports First Patient Dosing in the P-III Clinical Trial of ASC40 + Bevacizumab for Treatment of Recurrent Glioblastoma

Ascletis Reports First Patient Dosing in the P-III Clinical Trial of ASC40 + Bevacizumab for Treatment of Recurrent Glioblastoma

Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2022 PharmaShots - All Rights Reserved.